Esperion Therapeutics, Inc. (LON:0IIM)
3.423
+0.012 (0.36%)
Feb 12, 2026, 4:59 PM GMT
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $87.31M USD in the quarter ending September 30, 2025, with 69.10% growth. This brings the company's revenue in the last twelve months to $303.80M, up 2.83% year-over-year. In the year 2024, Esperion Therapeutics had annual revenue of $332.31M with 185.66% growth.
Revenue (ttm)
$303.80M
Revenue Growth
+2.83%
P/S Ratio
2.60
Revenue / Employee
$999.35K
Employees
304
Market Cap
587.62M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332.31M | 215.98M | 185.66% |
| Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
| Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
| Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
| Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
| Dec 31, 2019 | 148.36M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Spire Healthcare Group | 1.55B |
| CVS Group | 673.20M |
| Advanced Medical Solutions Group | 220.30M |
| Oxford Biomedica | 151.21M |
Esperion Therapeutics News
- 4 weeks ago - Esperion Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
- 4 weeks ago - Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up - Nasdaq
- 4 weeks ago - Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Therapeutics (ESPR) Set for Significant Growth with Cholesterol Drugs - GuruFocus
- 2 months ago - Piper Sandler Initiates Coverage on Esperion Therapeutics (ESPR) | ESPR Stock News - GuruFocus
- 3 months ago - Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha